SAPIEN M3 Commander M Delivery SystemWhat to know
30-second read
For Cardiology · Cardiothoracic Surgery
- Who
- Structural heart programs implanting Edwards’ SAPIEN M3 transcatheter mitral valve using a Commander M delivery system from one of four named lots.
- What FDA found
- Three reports of the delivery balloon bursting during inflation — one death, one serious injury — as of Edwards’ 5 October 2026 customer letter.
- Immediate concern
- A burst balloon can embolize material or block a vessel, or trap the delivery system and force emergency surgery, in patients generally judged unsuitable for surgery.
- What to check
- Whether any Commander M units on hand carry lot 67718561, 67804014, 67887043 or 67887044; other lots are not implicated and remain in use.
- Status
- FDA’s 15 October Early Alert is a high-risk notice, not yet a formal recall classification; the agency says it will update as more information arrives.
- Context
- A different delivery system burst balloons in 2019 (SAPIEN 3 Ultra, aortic, Class I recall, 17 injuries, 1 death) — a recurring failure mode, not the same device.
Practice impactCheck lots this week
Structural heart programs using SAPIEN M3 should check Commander M inventory against the four named lots now and report any balloon malfunction to FDA MedWatch; the valve itself is not implicated.
FDA posted an early alert on 15 October 2026 after Edwards Lifesciences told customers to remove and return four lots of the Commander M delivery system used to implant its SAPIEN M3 transcatheter mitral valve. Edwards wrote to hospitals on 5 October after receiving three reports of the delivery balloon bursting during inflation — one death, one serious injury. The valve itself is not implicated; the issue is confined to the delivery catheter that carries it into place. FDA says the action is a high-risk early alert, not yet a formal recall classification, and that it will update the public as the agency learns more.
What the Commander M balloon is doing
SAPIEN M3 is Edwards’ transseptal transcatheter mitral valve replacement (TMVR) system, approved by FDA in December 2025 as the first transseptal TMVR therapy on the U.S. market. It reaches the mitral valve through a 29F steerable guide sheath advanced from the femoral vein across the atrial septum, in a two-step procedure: the delivery system first places a self-expanding dock around the native valve, then delivers the balloon-expandable SAPIEN valve into that dock. The Commander M is the balloon-based delivery catheter used for that second step. FDA’s alert and Edwards’ customer letter describe the balloon bursting during inflation in three cases to date. A burst balloon mid-procedure creates two distinct hazards: fragments or trapped gas can embolize downstream and block a vessel, or the device itself can become difficult to retrieve, in some cases forcing an emergency surgical conversion — a serious proposition in a population selected for SAPIEN M3 specifically because a multidisciplinary heart team judged them poor candidates for open surgery.
How an early alert differs from a recall
This is not yet a Class I, II or III recall. FDA expanded its Early Alert program to all device types in September 2025, creating a channel for the agency to publicize a potentially high-risk issue before it has completed a formal recall classification — sometimes before the manufacturer has even finished its own internal risk assessment. The tradeoff for speed is that the picture can still be incomplete: FDA’s own language flags the issue as high-risk without committing to how many devices, patients or injuries are ultimately involved, and says it will post updates as the investigation continues. For a structural heart program, the practical distinction matters less than it sounds: four specific lots have been named, Edwards has already asked customers to pull and return them, and that instruction is actionable today whether or not FDA later classifies the action formally.
The four lots, and what is not affected
- Affected: Commander M delivery systems from lots 67718561, 67804014, 67887043 and 67887044 — the lots Edwards named in its 5 October customer letter and asked hospitals to remove from use and return.
- Not affected: Commander M delivery systems from any other lot, per the alert, are not implicated and can continue to be used.
- Not affected: the SAPIEN M3 valve itself. The issue is confined to the delivery catheter, not the implant.
- Not affected: Edwards’ other delivery platforms, including the Commander system used for SAPIEN 3 Ultra in the aortic position, which is a related but distinct product line with its own (2019) recall history — see below.
A familiar failure mode, a different valve
Burst delivery balloons are not new to this product family. In 2019, FDA classified a Class I recall — its most serious category — of the SAPIEN 3 Ultra delivery system after reports of balloons bursting during valve alignment, which Edwards addressed at the time with a field safety notice and a revised instruction to inflate the balloon slowly and continuously. FDA said 17 injuries and one death were reported in connection with that action, covering all lots of four specific delivery-system models. That recall involved the aortic valve program, a different device used in a different anatomic position from the mitral SAPIEN M3 launched six years later. The two events are not the same defect in the same product, and this story does not merge them. What they share is instructive on its own: a balloon-based transcatheter delivery system that must inflate reliably, under pressure, inside the heart, is a narrow engineering target, and this is the second time in seven years that Edwards has had to pull delivery-system lots over exactly that failure mode.
Mitral regurgitation: repair versus replacement options
| SAPIEN M3 (TMVR) | MitraClip / PASCAL (TEER) | |
|---|---|---|
| Mechanism | Replaces the native mitral valve via a balloon-expandable transcatheter valve, delivered into a pre-placed dock | Repairs the native valve by clipping the leaflets together, reducing regurgitant flow without replacing the valve |
| Typical candidate | Symptomatic moderate-to-severe or severe MR, or MR/MS with mitral annular calcification, unsuitable for surgery or TEER | Symptomatic MR where the leaflet anatomy is suitable for clip-based repair |
| Evidence base | ENCIRCLE: single-arm, 299 patients unsuitable for other options; 95.7% achieved MR grade 0/1+ at one year (presented at TCT, October 2025) | CLASP IID: randomized comparison of Edwards’ PASCAL against MitraClip in prohibitive-risk MR |
| This alert | Commander M delivery system: four lots recalled for balloon bursts; the valve is not implicated | Not involved in this alert |
ENCIRCLE and CLASP IID particulars from Edwards’ December 2025 approval announcement and trial registry listings; prescribe and select devices from current labeling, not this table.
What changes in the cath lab this week
- Check inventory now. Pull any Commander M delivery systems and check their lot numbers against 67718561, 67804014, 67887043 and 67887044. Quarantine any matches and follow Edwards’ return instructions from its 5 October customer letter.
- Do not cancel cases over unaffected lots. Per the alert, Commander M units outside the four named lots are not implicated and can continue to be used; SAPIEN M3 valves already implanted are not affected regardless of lot.
- Brief the heart team. Interventional cardiologists and cardiac surgeons scheduling or performing SAPIEN M3 cases this week should know the lot numbers and the balloon-burst failure mode before the next case, not after.
- Report what you see. Any balloon malfunction encountered during a procedure, whatever the lot, should go to FDA MedWatch — the reports behind this alert are how a high-risk signal becomes a clearer one.
- Watch for an update, not a conclusion. FDA has explicitly said more information is coming; this alert is a snapshot, not FDA’s final word on scope or classification.
How this alert arrived, and what to watch for
- Oct 27, 2025
ENCIRCLE one-year data presented
SAPIEN M3’s pivotal trial results presented at TCT and published in The Lancet.
- Dec 22, 2025
FDA approves SAPIEN M3
First transseptal transcatheter mitral valve replacement therapy cleared in the U.S.
- Oct 5, 2026
Edwards notifies customers
Letter asks hospitals to remove and return four Commander M delivery-system lots after three balloon-burst reports.
- Oct 15, 2026
FDA posts Early Alert
Agency labels the issue high-risk; no formal recall classification yet.
- Ahead
FDA says it will update
Scope, classification and corrective action may still change as the agency's review continues.
Sources & further reading
- FDA, “Early Alert: Transcatheter Mitral Valve Delivery System Issue from Edwards Lifesciences,” Medical Device Recalls and Early Alerts, 15 October 2026. fda.gov
- Reuters, “FDA flags Edwards Lifesciences heart-valve delivery system issue after death, injury,” 15 October 2026. massdevice.com
- Medical Device Network, “Edwards’ SAPIEN M3 delivery system linked to patient death in FDA alert,” 15 October 2026. medicaldevice-network.com
- Edwards Lifesciences, “FDA Approves Edwards Lifesciences’ SAPIEN M3 Mitral Valve Replacement System as First Transseptal Transcatheter Therapy,” 23 December 2025. businesswire.com
- FDA, “Class I Recall: Edwards Lifesciences SAPIEN 3 Ultra Delivery System,” August 2019 (background on the related 2019 aortic delivery-system recall). tctmd.com
Regulatory News reports on public regulatory documents. It is not legal advice, and the primary sources above govern. Several granular details in this story (the exact lot count and balloon-burst count) trace to secondary reporting of Edwards’ customer letter rather than a directly verified FDA or Edwards primary-source document, because this environment could not independently fetch either; we will update this story if FDA’s posted scope differs. If we have made an error, we will say so in public: see corrections.
Frequently asked questions
Is the SAPIEN M3 valve itself affected, or just the delivery system?
Just the delivery system. FDA's early alert and Edwards' customer letter describe a balloon-rupture issue in the Commander M delivery catheter used to implant SAPIEN M3 — the steerable sheath and balloon that carries the valve into place — not a defect in the valve itself. The four named lots are delivery-system lots; SAPIEN M3 valves already implanted are not affected by this alert.
What should a structural heart program do right now?
Check inventory for Commander M delivery systems against lot numbers 67718561, 67804014, 67887043 and 67887044. If any are on hand, quarantine them and contact Edwards for return instructions per the company's 5 October customer letter. Delivery systems from other lots are not implicated and, per the alert, can continue to be used. Report any balloon malfunction encountered during a procedure to FDA MedWatch.
Is this the same problem as the 2019 SAPIEN 3 Ultra recall?
No, though the failure mode rhymes. In 2019, FDA classified a Class I recall of the SAPIEN 3 Ultra delivery system — used for the aortic valve, not the mitral valve — after burst balloons caused 17 injuries and one death. This is a different device, a different valve position and a different year; FDA's October 2026 action is an early alert, not yet a formal recall classification. The pattern of a bursting delivery balloon is the detail worth carrying forward, not the specific event.
